IRLAB launches Phase Ib Trial of IRL757 for Parkinson’s patients with Apathy
The multicenter study will enroll 75 patients across 16 sites in Germany, Bulgaria, Poland, and Spain
The multicenter study will enroll 75 patients across 16 sites in Germany, Bulgaria, Poland, and Spain
Masitinib targets mast cells, which play a critical role in severe forms of SCD and its complications, including vaso-occlusive crises, acute chest syndrome, and pain
Study published in laboratory investigation, the official journal of the United States and Canadian Academy of Pathology
Shonan iPark was chosen for its globally connected life-science ecosystem, which unites pharmaceutical firms, next-generation medicine developers, AI and digital health innovators, venture capital, and academia
AFib is a progressive condition where timely intervention is critical to disease management and, ultimately, the patient's quality of life
The Phase 1 study will evaluate the safety, tolerability, and pharmacokinetics (PK) of ENV-6946 in healthy volunteers
Adverse events were consistent with valbenazine’s established safety profile
Subscribe To Our Newsletter & Stay Updated